Clinical trials: Androgen Deprivation Therapy
Prostate Carcinoma
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer .
- Trial name
- NCT04600336
- Testing
- Oxybutynin Chloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 103 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Training for Men Undergoing Androgen Deprivation Therapy.
The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).
- Trial name
- ADT-train (NCT06449664)
- Testing
- ADT-train
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- The Swedish School of Sport and Health Sciences
Cancer Of Prostate
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Background: Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment.
- Trial name
- NCT05361798
- Testing
- PDS01ADC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Prostate Cancer
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
The widespread availability of screening coupled with high risks of over diagnosis, over treatment, and a rising risk of dying from competing causes of deaths pose a major challenge for prostate cancer patients and our health…
- Trial name
- NCT00161252
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Gastrointestinal Complications, Prostate Cancer
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications
- Trial name
- NCT00541047
- Testing
- bicalutamide, goserelin acetate, leuprolide acetate
- Where
- 58 sites in Canada, United Kingdom
- Volunteers
- 4,236 people
- Sponsor
- University College, London
Prostate CA
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although…
- Trial name
- NCT06834321
- Testing
- Homoharringtonine combined with androgen deprivation therapy, radical prostatectomy
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- baotai Liang
Advanced Prostate Carcinoma
Physical Function During ARSI Treatment
This single arm observational pilot study aims to determine the longitudinal effects of androgen receptor signaling inhibitors (ARSI) in men with advanced prostate cancer.
- Trial name
- NCT05612880
- Testing
- androgen receptor signaling inhibitors
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Prostate Cancer, Lower Urinary Tract Symptoms
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms…
- Trial name
- LEMON (NCT01078545)
- Testing
- Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
- Where
- 143 sites in Poland, Ukraine
- Volunteers
- 729 people
- Sponsor
- Abbott
Prostate Cancer
PROState Cancer Patients Initiating Hormone Therapy: Effect of Exercise on CARDIOvascular Health (PROSCARDIO)
This study evaluates whether exercise can reduce treatment-related adverse effects in prostate cancer patients initiating androgen deprivation therapy.
- Trial name
- PROSCARDIO (NCT03776045)
- Testing
- Standard care plus exercise
- Volunteers
- 50 people
- Sponsor
- University of East Anglia
Prostate Cancer Recurrent
Firmagon (Degarelix) Intermittent Therapy
Men with localized prostate cancer requiring intermittent androgen deprivation therapy for biochemical recurrence following radical therapy will be asked to participate in a phase 4 safety and efficacy clinical trial comparing 10…
- Trial name
- FIT (NCT01512472)
- Testing
- degarelix
- Where
- 15 sites in Canada
- Volunteers
- 144 people
- Sponsor
- Canadian Urology Research Consortium
Prostatic Neoplasms
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
- Trial name
- ARANOTE (NCT04736199)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Androgen deprivation therapy (ADT)
- Where
- 131 sites in Australia, Brazil and 13 more
- Volunteers
- 669 people
- Sponsor
- Bayer
Cancer of Prostate
De-implementation of Low Value Castration for Men With Prostate Cancer
This study will use a theory-based, mixed methods approach to identify, tailor and pilot two different de-implementation strategies that vary widely in delivery, impact, and expected results for reducing low value androgen…
- Trial name
- DeADT (NCT03579680)
- Testing
- ADT ORDER CHECK ATTESTATION (OR), PROVIDER SCRIPT (SC)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Prostate Cancer
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
This is an open label non-comparative controlled randomized phase II study. The experimental arm is the group receiving ODM-201. The group receiving androgen-deprivation therapy (ADT) is included as an internal control.
- Trial name
- NCT02972060
- Testing
- ODM-201, ADT
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 61 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
The principal objectives of the RADAR trial is to address the hypotheses; 1) that 18 months androgen deprivation in conjunction with radiotherapy is superior to 6 months androgen deprivation prior to and during radiotherapy; 2)…
- Trial name
- NCT00193856
- Testing
- Leuprorelin Acetate, Zoledronic Acid, Conventional external beam therapy
- Where
- 24 sites in Australia, New Zealand
- Volunteers
- 1,071 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7
Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
This study collects urine and stool samples to determine the ability to identify changes in the microbiome (bacteria, fungi, and viruses that live in the gut and urine) of patients with prostate cancer during androgen deprivation…
- Conditions
- Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
- Trial name
- NCT04775355
- Testing
- Biospecimen Collection, Electronic Health Record Review, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Prostatic Neoplasms
Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
The goal of this clinical trial is to learn if a low to moderate load power training program is feasible and effective for improving fitness and quality of life of people with prostate cancer under androgen suppression therapy…
- Trial name
- NCT07572760
- Testing
- Power training group
- Where
- Spain
- Volunteers
- 66 people
- Sponsor
- University of Alicante
Prostate Cancer
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Protocol G200712 is a Phase II, exploratory study to assess the effects of GTx-758 on serum prostate specific antigen (PSA) response ans serum PSA progression in men with Metastatic Castration Resistant Prostate Cancer (mCRPC) on…
- Trial name
- NCT01615120
- Testing
- GTx-758 125 mg, GTx-758 250 mg
- Where
- 26 sites in United States
- Volunteers
- 77 people
- Sponsor
- GTx
Prostate Cancer
Effect of ADT in Chinese Male With Prostate Cancer
Many prostate cancer patients required the use of androgen deprivation therapy (ADT) for the control of disease. In this study, the investigators aim at assessing the different in various parameters between PCa patients received…
- Trial name
- NCT04341324
- Testing
- It is an observational study.
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
This phase II trial studies the side effects and how well abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy works in treating patients with localized or locally advanced…
- Conditions
- Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- RAD1 (NCT01023061)
- Testing
- abiraterone acetate, prednisone, leuprolide acetate
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Washington